Harvist and others reported a few days ago the announcement by NICE of a cull in the various COVID medicines approved for NHS use. As a result, the options for treating immunocompromised individuals with COVID soon after symptoms appear, thereby avoiding progression, would be reduced to just one antiviral, Paxlovid, which for certain individuals including CLL patients is contraindicated. healthunlocked.com/cllsuppo...
The announcement by NICE is actually a DRAFT PROPOSAL FOR PUBLIC CONSULTATION. nice.org.uk/news/article/ni... so there is every opportunity for us to make our views known.
As most people will know, none of the approved monoclonal antibody medicines can be relied upon effectively to treat COVID variants now dominant or likely to be over the coming winter. We are left with two antivirals that are authorised to be given within 5 days of onset of symptoms - Paxlovid and Molnupiravir - and one within 7 days - Remdesivir.
Contrary to doubt cast by NICE on the effectiveness of the latter two drugs, all published lab studies to date have shown them to neutralise all COVID variants, including emerging variants of concern. At least, I don't know of any such studies showing otherwise. Nor do I know of any relevant clinical studies. If anyone does, please shout!
In any case, Paxlovid and Molnupiravir each have their own, quite serious contraindications. A percentage of immunocompromised individuals with COVID will not be able to use one or the other, and for a minority neither will be an option. Unlike the other two, Remdesivir is not an oral medicine, and must be given by infusion in an outpatient setting. Despite this inconvenience, NICE should ensure it remains on the CMDU menu.
To make your voice heard, you can of course
write to NICE direct, as it's a public consultation, at any stage. Right now, it seems a good idea to stir up the blood cancer charities who are big on patient advocacy e.g.
bloodcancer.org.uk/about-us... BCUK's website makes no mention of the issue in the COVID treatments page. I would expect BCUK to get on the case, and to give some immediate feedback to an email.